SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted

• Main Authors: Manuela Mancini (Author), Cecilia Monaldi (Author), Sara De Santis (Author), Cristina Papayannidis (Author), Michela Rondoni (Author), Chiara Sartor (Author), Samantha Bruno (Author), Livio Pagano (Author), Marianna Criscuolo (Author), Roberta Zanotti (Author), Massimiliano Bonifacio (Author), Patrizia Tosi (Author), Michel Arock (Author), Peter Valent (Author), Michele Cavo (Author), Simona Soverini (Author)
• Format: Book
• Published: BMC, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background The SETD2 tumor suppressor gene encodes a histone methyltransferase that safeguards transcription fidelity and genomic integrity via trimethylation of histone H3 lysine 36 (H3K36Me3). SETD2 loss of function has been observed in solid and hematologic malignancies. We have recently...